Double-blind, placebo-controlled trial investigating the safety of re-exposure to 900 mg of Org 34517, used as adjunctive therapy in subjects with psychotic major depression (major depressive episode, severe, with psychotic features), who participated in Trial 28130.
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2015
At a glance
- Drugs ORG 34517 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Organon
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
- 19 Feb 2009 New trial record